2511 — HighTide Therapeutics Balance Sheet
0.000.00%
- HK$803.80m
- HK$364.54m
Annual balance sheet for HighTide Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Cash | ||||
Short Term Investments | ||||
Cash and Short Term Investments | 765 | 840 | 736 | 491 |
Net Total Receivables | 3.64 | 2.34 | 16.3 | 10.9 |
Prepaid Expenses | ||||
Total Other Current Assets | ||||
Total Current Assets | 775 | 851 | 779 | 513 |
Gross Property, Plant And Equipment | ||||
Accumulated Depreciation | ||||
Net Property, Plant And Equipment | 3.45 | 4.81 | 15 | 23.9 |
Other Long Term Assets | ||||
Total Assets | 779 | 856 | 795 | 560 |
Accounts Payable | ||||
Accrued Expenses | ||||
Notes Payable / Short Term Debt | ||||
Current Portion of Long Term Debt / Capital Leases | ||||
Total Other Current Liabilities | ||||
Total Current Liabilities | 28.5 | 1,320 | 79.8 | 110 |
Long Term Debt | ||||
Capital Lease Obligations | ||||
Total Long Term Debt | ||||
Total Debt | ||||
Total Other Liabilities | ||||
Total Liabilities | 1,051 | 1,326 | 92.3 | 136 |
Common Stock | ||||
Additional Paid In Capital | ||||
Retained Earnings (Accumulated Deficit) | ||||
Treasury Stock | ||||
Other Equity | ||||
Total Equity | -272 | -471 | 703 | 424 |
Total Liabilities & Shareholders' Equity | 779 | 856 | 795 | 560 |
Total Common Shares Outstanding |